Navigation Links
Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Date:12/5/2012

ted therapy ineffective.  The authors concluded that in this study the combination of brostallicin and cisplatin showed promising activity in heavily pretreated metastatic triple-negative breast cancer patients and achieved its primary endpoint comparing favorably to other Phase 2 clinical trials in this disease.  Final results of this trial are expected to be presented at the American Society of Clinical Oncology 2013 Annual Meeting. A follow-up randomized Phase 2 trial is in development.

About Triple-negative Breast Cancer

This term is used to describe breast cancers (usually invasive ductal carcinomas) whose cells lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces. Breast cancers with these characteristics tend to occur more often in younger women and in African-American women. Triple-negative breast cancers tend to grow and spread more quickly than most other types of breast cancer. Because the tumor cells lack these certain receptors, neither hormone therapy nor drugs that target HER2 are effective treatments (but chemotherapy can still be useful if needed). About 10% to 20% of breast cancers are triple negative.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies.

About Cell Therapeutics, Inc.

Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making canc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
4. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
5. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
6. United Therapeutics Corporation To Announce Third Quarter 2012 Financial Results Before Market Open On Thursday, November 1, 2012
7. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
8. Alzheimers Therapeutics Reviewed by NeuroPerspective
9. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MN , April 30, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has commenced an ... BioAmber expects to grant the underwriters a 30-day option ... the shares of common stock offered in the public ... there can be no assurance as to whether or ...
(Date:4/30/2015)... The following is an open letter sent April ... Blood Corp (NYSE: CO ) from Jayhawk Capital. ... directors of China Cord Blood Corp (" China Cord ") ... share from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, ... benefit Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics including high value ... closing of its previously announced underwritten public offering ... a public offering price of $15.50 per share. ... underwriters of their option to purchase up to ...
(Date:4/30/2015)... 30, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... global contract R&D services provider, today announced that its ... letter, dated April 29, 2015, from a consortium (the ... "Chairman"), founder, chairman and chief executive officer of the ... proposes a transaction (the "Transaction") involving the acquisition of ...
Breaking Biology Technology:BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... May 13 Xennex, Inc. (Xennex) announced today ... of Version 3.0 beta, available at ... 3.0 features a significantly upgraded infrastructure, including a ... and speedier search engine. It provides capabilities for ...
... OF INDUSTRY, Calif. and HONG KONG, May 13 ... that its 49% owned subsidiary, Excalibur International Marine Corporation, ... Taiwan Strait between Taiwan and Mainland China. Excalibur,s ... and is capable of carrying over 300 tons of ...
... DIEGO, May 12 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Care Conference on Tuesday, May 19, 2009 at ... Daniel M. Bradbury, president and chief executive officer of Amylin ... session will be webcast, and a recording will be made ...
Cached Biology Technology:GeneCards(R) Version 3.0 Beta Released 2GeneCards(R) Version 3.0 Beta Released 3EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 2EFT BioTech Holdings, Inc.'s Subsidiary Receives First Permit to Cross Taiwan Strait 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... TORONTO A study led by scientists at The ... identifying drugs to treat children suffering from fatal cancers for ... developing a new drug from scratch, which is a complicated ... lab, they tested existing drugs on cancer stem cells from ...
... at Montana State University have developed six new biomedical ... infections, fungal infections and viral infections; boosting humans, innate ... The technologies are available for licensing to ... involves an existing clinical drug that was discovered to ...
... Market - Advanced Technologies, Global Forecast and Winning Imperatives... -- DALLAS, August 18, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology News:Scientists find new twist on drug screening to treat common childhood cancer 2Scientists find new twist on drug screening to treat common childhood cancer 3Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 2New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 3New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 4New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 5New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 6New Report - Bioinformatics Market - Advanced Technologies, Global Forecast and Winning Imperatives (2009 - 2014) By MarketsandMarkets 7
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
Biology Products: